AstraZeneca's breast cancer drug fails in late-stage trial

AstraZeneca's breast cancer drug Etcamah did not meet its main goal in a late-stage trial. The drug showed only a numerical improvement when combined with palbociclib. This marks a setback for the recently approved treatment, which received accelerated approval. U.S.-listed shares of AstraZeneca experienced a decline in aftermarket trading. Trial data will be shared by the company in due course.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/mdZjpwy
via IFTTT